February 2022—Roche announced that the FDA has granted emergency use authorization for its COVID-19 At-Home Test. The test uses an anterior nasal swab sample that can be self-collected and self-tested by people ages 14 years and older and by an adult for children ages two to 13 years old. Results are available in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including omicron.
Roche will offer Navify Pass with the COVID-19 At-Home Test as a solution to organizations that want to allow individuals and health care professionals to remotely and securely store, display, and share results. The at-home tests are supplied with a unique data matrix, enabling Navify Pass to automatically link individuals’ test results to their respective test devices.
The test is available in the United States and in accordance with local guidelines and testing strategies. The launch is in partnership with SD Biosensor, with which Roche has a global distribution agreement.
Roche, 317-521-2000